JPRN-C000000120
Completed
Phase 2
Randomized phase II study of irinotecan and cisplatin or irinotecan, cisplatin and etoposide in patients with extensive small-cell lung cancer - Randomized phase II study of IP vs IPE for E-SCLC
Division of Medical Oncology, National Cancer Center Hospital0 sites110 target enrollmentJune 1, 2006
ConditionsExtensive small-cell lung cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Extensive small-cell lung cancer
- Sponsor
- Division of Medical Oncology, National Cancer Center Hospital
- Enrollment
- 110
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) uncontrollable pleural, pericardial effusion or ascites; 2\) symptomatic brain metastasis; 3\) active infection;4\) contraindications for the use of irinotecan, including diarrhea, ileus, interstitial pneumonitis and lung fibrosis; 5\) synchronous active malignancies; 6\) serious concomitant medical illness, including severe heart disease, uncontrollable diabetes mellitus or hypertension; or 7\) pregnancy or breast feeding.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Randomized, phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small-cell lung cancer HOT1401/NJCLG1401JPRN-UMIN000013882orth Japan Lung Cancer Study Group and Hokkaido Lung Cancer Clinical Study Group80
Unknown
Not Applicable
A randomized phase 2 trial of Irinotecan/Paclitaxel versus Irinotecan/Gemcitabine in patient with stage IIIB/IV non small cell lung cancer.JPRN-jRCT1080220109Yakult Honsha Co.,Ltd.
Completed
Not Applicable
Randomized Phase III Trial of Irinotecan plus Cisplatin vs. bi-weekly Irinotecan after S-1 failure for Patients with Advanced and Recurrent Gastric CancerS-1 failure for Patients with Advanced and Recurrent Gastric CancerJPRN-UMIN000001028The Tokyo cooperative oncology group130
Completed
Phase 3
A Phase III Study Comparing Irinotecan and Cisplatin with Etoposide and Cisplatin for Adjuvant Chemotherapy of Completely Resected Pulmonary High-grade Neuroendocrine Carcinoma (JCOG1205/1206, HGNEC-EP/IP-P3)Pathological stage I-IIIA completely resected pulmonary high-grade neuroendocrine carcinomaJPRN-UMIN000010298Japan Clinical Oncology Group (JCOG)220
Active, not recruiting
Phase 1
Medical treatment for patients with cancer of the esophagus or stomachPatients with esophagus or gastric cancer and who are platinum resistant and non-resectabelMedDRA version: 14.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002321-30-DKOdense University Hospital